Pancreatic ductal adenocarcinomas (PDACs) are highly metastatic with poor prognosis, mainly
due to delayed detection. We hypothesized that intercellular communication is critical for …

Cellular reprogramming—the ability to interconvert distinct cell types with defined factors—is
transforming the field of regenerative medicine. However, this phenomenon has rarely been …

Metastasis is the leading cause of cancer-associated death but has been difficult to study
because it involves a series of rare, stochastic events. To capture these events, we developed …

Sonic hedgehog (Shh), a soluble ligand overexpressed by neoplastic cells in pancreatic
ductal adenocarcinoma (PDAC), drives formation of a fibroblast-rich desmoplastic stroma. To …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in
the United States with a median survival of <6 mo and a dismal 5-yr survival rate of 3%–5%. …

Ligation of the extracellular domain of the cell surface receptor Fas/APO-1 (CD95) elicits a
characteristic programmed death response in susceptible cells. Using a genetic selection …

KRAS mutant pancreatic ductal adenocarcinoma (PDAC) is characterized by a desmoplastic
response that promotes hypovascularity, immunosuppression, and resistance to chemo- …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, lethal malignancy that invades
adjacent vasculatures and spreads to distant sites before clinical detection. Although …

Most cancer-associated deaths result from metastasis. However, it remains unknown whether
the size, microenvironment or other features of a metastatic lesion dictate its behaviour or …

Activating KRAS mutations are found in over 90% of pancreatic ductal adenocarcinomas (PDACs),
yet KRAS has remained a difficult target to inhibit pharmacologically. Here, we …